Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OBI Pharma's Total Assets for the quarter that ended in Dec. 2025 was NT$3,421.27 Mil.
During the past 12 months, OBI Pharma's average Total Assets Growth Rate was -11.40% per year.
During the past 3 years, the average Total Assets Growth Rate was 6.30% per year.
During the past 5 years, the average Total Assets Growth Rate was 8.90% per year.
During the past 10 years, the average Total Assets Growth Rate was 1.60% per year.
During the past 13 years, OBI Pharma's highest 3-Year average Total Assets Growth Rate was 219.30%. The lowest was -40.70%. And the median was 15.85%.
Total Assets is connected with ROA %. OBI Pharma's annualizedROA % for the quarter that ended in Dec. 2025 was -46.28%. Total Assets is also linked to Revenue through Asset Turnover. OBI Pharma's Asset Turnover for the quarter that ended in Dec. 2025 was 0.01.
Note:
The Net Income data used here is four times the quarterly (Dec. 2025) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
OBI Pharma's Asset Turnover for the quarter that ended in Dec. 2025 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
OBI Pharma Total Assets Related Terms
OBI Pharma Total Assets Historical Data
* Premium members only.
The historical data trend for OBI Pharma's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
OBI Pharma's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OBI Pharma (ROCO:4174) has a Total Assets of NT$3,421.27 Mil as of Dec. 2025. The total amount of assets as recorded on a company's balance sheet. View historical data on OBI Pharma and its competitors.
Is OBI Pharma's Total Assets too high?
OBI Pharma's current Total Assets is NT$3,421.27 Mil. Overall, OBI Pharma has a GF Score™ of 45/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does OBI Pharma's Total Assets compare to VRTX and REGN?
OBI Pharma's Total Assets of NT$3,421.27 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on OBI Pharma and its competitors. OBI Pharma's current Total Assets is NT$3,421.27 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OBI Pharma stock overvalued right now?
Based on GuruFocus' analysis, OBI Pharma (ROCO:4174) is currently considered Possible Value Trap. The stock's GF Value™ is NT$138.67, compared to a current price of NT$28.65 — trading 79.3% below its estimated fair value. The current Total Assets is NT$3,421.27 Mil. OBI Pharma's overall GF Score™ is 45/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For OBI Pharma (ROCO:4174), the current Total Assets is NT$3,421.27 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is OBI Pharma (ROCO:4174) Overvalued in 2026?
Based on GuruFocus' analysis, OBI Pharma stock appears to be undervalued.
The current stock price of NT$28.65 is trading 79.3% below its estimated GF Value™ of NT$138.67.
GuruFocus considers OBI Pharma to be Possible Value Trap.
Key valuation signals for ROCO:4174:
Total Assets: NT$3,421.27 Mil
GF Value™: NT$138.67 vs. price of NT$28.65 (79.3% below fair value)
No single metric tells the full story. See the ROCO:4174 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
OBI Pharma Inc is engaged in the research and development of novel therapeutic agents and biologics for patients with unmet medical needs. The company has three reportable segments: the anti-cancer new drug segment, the botulinum toxin new drug segment, and the CDMO segment. Geographically, it generates the majority of its revenue from Taiwan.
45GF Score
Get the complete analysis for ROCO:4174
Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4174 has been successfully added to your 
